While clinical practice typically relies on serum TT measurements, it is important to recognize that testosterone exerts its effects either through direct binding to androgen receptors in prostate tissue or via conversion to dihydrotestosterone by 5α-reductase, subsequently regulating prostate cancer development and progression (14, 15). This evidence concerns the gene AR and prostate carcinoma.